Patients
Healthcare Professionals
Santen Corporate (EN)
menu
Who We Are
Who We Are
Menu Top
Who We Are
Message from the CEO
Who We Are
Message from the CEO
Santen’s Corporate Philosophy Framework
Who We Are
Santen’s Corporate Philosophy Framework
History of Santen
Who We Are
History of Santen
Corporate Executives
Who We Are
Corporate Executives
Corporate Governance
Who We Are
Corporate Governance
Digital Transformation
Who We Are
Digital Transformation
Policies and Statements
Who We Are
Policies and Statements
Overview / Map
Who We Are
Overview / Map
Global Operations
Who We Are
Global Operations
What We Do
What We Do
Menu Top
What We Do
Medium-Term Management Plan
What We Do
Medium-Term Management Plan
Efforts to Enhance Patients’ Satisfaction
What We Do
Efforts to Enhance Patients’ Satisfaction
Efforts to Enhance Product Usability
Efforts to Enhance Patients’ Satisfaction
Efforts to Enhance Product Usability
Efforts to Address Untreated Patients
Efforts to Enhance Patients’ Satisfaction
Efforts to Address Untreated Patients
Research & Development
What We Do
Research & Development
The Ophthalmic Development Process
Research & Development
The Ophthalmic Development Process
Clinical Trial Information
Research & Development
Clinical Trial Information
Production and Quality Assurance
What We Do
Production and Quality Assurance
Production
Production and Quality Assurance
Production
Safety and Quality Assurance
Production and Quality Assurance
Safety and Quality Assurance
The Ophthalmic Production Process
Production and Quality Assurance
The Ophthalmic Production Process
Partnering
What We Do
Partnering
Santen's Partnership
Partnering
Santen's Partnership
Our Partners
Partnering
Our Partners
Partnering Contact
Partnering
Partnering Contact
Sustainability
Sustainability
Menu Top
Sustainability
Sustainability at Santen
Sustainability
Sustainability at Santen
Environment
Sustainability
Environment
Social
Sustainability
Social
Governance
Sustainability
Governance
Sustainability Library
Sustainability
Sustainability Library
Investor Relations
Investor Relations
Menu Top
Investor Relations
Company Information
Investor Relations
Company Information
Message from the CEO
Company Information
Message from the CEO
Santen’s Corporate Philosophy Framework
Company Information
Santen’s Corporate Philosophy Framework
Medium-Term Management Plan
Company Information
Medium-Term Management Plan
Corporate Governance
Company Information
Corporate Governance
Corporate Executives
Company Information
Corporate Executives
Forward-Looking Statement
Company Information
Forward-Looking Statement
Sustainability
Investor Relations
Sustainability
Sustainability at Santen
Sustainability
Sustainability at Santen
Environment
Sustainability
Environment
Social
Sustainability
Social
Governance
Sustainability
Governance
Library
Sustainability
Library
Sustainability Report
Sustainability
Sustainability Report
IR Library
Investor Relations
IR Library
Latest IR Documents
IR Library
Latest IR Documents
Consolidated Performance
IR Library
Consolidated Performance
Presentation Materials・Videos
IR Library
Presentation Materials・Videos
Integrated Report (Annual Report)
IR Library
Integrated Report (Annual Report)
Data Book
IR Library
Data Book
Pipeline
IR Library
Pipeline
Accounting Standards and Definition of "Core Basis"
IR Library
Accounting Standards and Definition of "Core Basis"
Stock Information
Investor Relations
Stock Information
Stock Information
Stock Information
Stock Information
Materials for the General Meeting of Shareholders
Stock Information
Materials for the General Meeting of Shareholders
Distribution of Profits to Shareholders and Dividends
Stock Information
Distribution of Profits to Shareholders and Dividends
IR Calendar
Stock Information
IR Calendar
Analyst Coverage
Stock Information
Analyst Coverage
Innovation
Investor Relations
Innovation
Efforts to Enhance Patients' Satisfaction
Innovation
Efforts to Enhance Patients' Satisfaction
Research and Development
Innovation
Research and Development
Production
Innovation
Production
Safety and Quality Assurance
Innovation
Safety and Quality Assurance
Careers
Careers
Menu Top
Careers
Our Stories
Our Stories
Menu Top
Our Stories
News
News
Menu Top
News
Home
News
2015 Press Release
RSS
Press Release
11.04.2015
NICE recommends the use of IKERVIS® in England for the treatment of severe keratitis in adult patients with dry eye disease
11.04.2015
Santen Reports Consolidated Performance For the First Half of FY2015
11.04.2015
Santen Announces Financial Result for the Second Quarter ended September 30, 2015
09.01.2015
Notice on Details of Subscription Rights to New Shares (Stock Options for Stock-Linked Remuneration)
08.25.2015
Santen Announces Approval of TAPROS for the Treatment of Open-Angle Glaucoma and Ocular Hypertension in China
08.04.2015
Santen to Grant Subscription Rights to New Shares as Stock Options for Stock-Linked Remuneration
08.04.2015
Santen Announces Financial Result for the First Quarter ended June 30, 2015
08.03.2015
Notice of Completion of the Transfer of Anti-Rheumatic Pharmaceutical Business to AYUMI Pharmaceutical Corporation
07.15.2015
Santen Launches Ikervis in Germany
07.01.2015
TRACON Pharmaceuticals Announces IND Filing of DE-122 (TRC105) for the Treatment of Wet Age-Related Macular Degeneration by Santen Pharmaceutical
06.26.2015
Intravitreal VEGF Inhibitor "EYLEA" Approved as a Treatment of Retinal Vein Occlusion(RVO)
06.24.2015
Santen Launches COSOPT Mini Combination ophthalmic solution for the Treatment of Glaucoma and Ocular Hypertension
06.10.2015
Notice of the appointment of Corporate Officers
05.12.2015
Santen Announces Assignment of its Anti-Rheumatic Pharmaceuticals Business to Hyperion Pharma Co., Ltd.
05.12.2015
Santen Reports Consolidated Performance for the Fiscal Year Ended March 31, 2015
05.12.2015
Notice of Member of the Board and Corporate Auditors Nominations
05.12.2015
Financial Results for the Fiscal Year Ended March 31, 2015
05.01.2015
Santen Makes Contributions to Support the Recovery of Areas Affected by the Earthquake in Nepal
04.27.2015
Santen Launches New Sante de U α, an OTC Eye Drop
04.10.2015
Notice of Change in Significant Shareholder
03.25.2015
Santen Announces Approval of Ikervis for EU Marketing Authorization
03.24.2015
Revision of consolidated earnings forecasts for FY 2014
03.24.2015
Santen Announces Proposed Dividends Change
03.12.2015
Santen Announces Approval of Glaucoma and Ocular Hypertension Therapeutic,COSOPT Mini Ophthalmic Solution in Japan
03.10.2015
Notice of the appointment of Corporate Officers
03.05.2015
Santen to Co-sponsor "Green Light-Up"to Illuminate Landmark Facilities in Green in Japan during the World Glaucoma Week from March 8, 2015 to March 14, 2015
03.02.2015
European Medicines Agency Accepts Santen's Marketing Application Filing for Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis of the Posterior Segment
02.24.2015
Santen Announces Stock Split and Amendment to the Articles of Incorporation
02.02.2015
Santen Launches Sante Lutax®20+Vitamin& Mineral a Nutritional Supplement Containing Lutein
01.23.2015
Santen receives a Positive CHMP Opinion for EU Marketing Authorization for Ikervis®
News Archive